EUVIMEDEUVIMED entdecken
Systematische ÜbersichtLeitlinieOpen Access

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

Van K Morris iD, Erin B Kennedy iD, Nancy N Baxter iD, Al B Benson iD, Andrea Cercek iD, May Cho, Kristen K Ciombor iD, Chiara Cremolini iD, Anjee Davis, Dustin A Deming iD, Marwan G Fakih iD, Sepideh Gholami iD und 9 weitere

Journal of Clinical Oncology · 20.01.2023 · 41 (3) · 678-700

DOI: 10.1200/jco.22.01690 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2023. Verfasst von Van K Morris und 20 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 678-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria. RECOMMENDATIONS Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti–vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti–epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti–vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E–mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsCetuximabEndothelial Growth FactorsPractice Guidelines as Topic

Substanzen

CetuximabEndothelial Growth Factors

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • American Society of Clinical Oncology, Alexandria, VA.
  • Melbourne School of Population and Public Health, Melbourne, Australia.
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • UCI Health, Irvine, CA.

ORCID-Profile: Van K Morris, Erin B Kennedy, Nancy N Baxter, Al B Benson, Andrea Cercek, Kristen K Ciombor, Chiara Cremolini, Dustin A Deming, Marwan G Fakih, Sepideh Gholami, Theodore S Hong, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H Strickler, Jason A Willis, Cathy Eng

Förderung

  • NCI NIH HHS

Zitieren

APA

Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., Fakih, M. G., Gholami, S., Hong, T. S., Jaiyesimi, I., Klute, K., Lieu, C., Sanoff, H., Strickler, J. H., White, S., …, & Eng, C. (2023). Treatment of Metastatic Colorectal Cancer: ASCO Guideline. Journal of Clinical Oncology, 41(3), 678-700. https://doi.org/10.1200/jco.22.01690

Vancouver

Morris VK, Kennedy EB, Baxter NN, Benson AB, Cercek A, Cho M, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. Journal of Clinical Oncology. 2023;41(3):678-700. doi:10.1200/jco.22.01690

BibTeX
@article{Morris2023,
  author = {Morris, Van K and Kennedy, Erin B and Baxter, Nancy N and Benson, Al B and Cercek, Andrea and Cho, May and Ciombor, Kristen K and Cremolini, Chiara and Davis, Anjee and Deming, Dustin A and Fakih, Marwan G and Gholami, Sepideh and Hong, Theodore S and Jaiyesimi, Ishmael and Klute, Kelsey and Lieu, Christopher and Sanoff, Hanna and Strickler, John H and White, Sarah and Willis, Jason A and Eng, Cathy},
  title = {Treatment of Metastatic Colorectal Cancer: ASCO Guideline},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {3},
  pages = {678--700},
  doi = {10.1200/jco.22.01690}
}
Kostenlos starten →